Dermatology and Dermatologic Diseases

ISSN: 2376-0427

Open Access

New Therapeutic Opportunities in Dermatology: Low Dose Cytokines Treatment for Vitiligo


Lotti T, Hercogova J and Fabrizi G

Vitiligo is a skin disorder characterized by skin depigmentation caused by the loss of melanocytes. The causes of melanocyte loss are unclear, but a relevant number of observations lead researchers to ascribe cellular immunity as having an important role in vitiligo pathogenesis. Acting at the origin of the inflammatory phenomena, rebalancing the immune response with specific low dose SKA interleukins and antibodies and stimulating melanocytes to produce melanin via up-regulation of transmembrane receptors through SKA low dose basic-Fibroblast Growth Factor, represents the proposed Low Dose Medicine approach for Vitiligo treatment.


Share this article

Recommended Conferences

Trauma, Emergency Medicine & Critical Care

Rome, Italy

Wound Care, Cell & Tissue Congress 2020

San Francisco, USA
arrow_upward arrow_upward